Patents by Inventor Deborah L. Higgins
Deborah L. Higgins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6395724Abstract: Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is a moiety capable of binding to COX-2. The multibinding compounds of this invention are useful in the treatment inflammation, pain, fever and the like.Type: GrantFiled: June 7, 1999Date of Patent: May 28, 2002Assignee: Advanced Medicine, Inc.Inventors: J. Kevin Judice, Deborah L. Higgins, John H. Griffin
-
Patent number: 5840564Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: September 9, 1997Date of Patent: November 24, 1998Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Bottstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5821105Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: October 17, 1996Date of Patent: October 13, 1998Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstkin, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5770426Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: June 12, 1996Date of Patent: June 23, 1998Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5770425Abstract: Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.Type: GrantFiled: July 18, 1994Date of Patent: June 23, 1998Assignee: Genentech, Inc.Inventors: Stephen P. Anderson, Deborah L. Higgins, Adair J. Hotchkiss, Cara B. Marks
-
Patent number: 5728567Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: August 1, 1996Date of Patent: March 17, 1998Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5714145Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: October 17, 1996Date of Patent: February 3, 1998Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5616486Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: April 14, 1995Date of Patent: April 1, 1997Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5614190Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: April 26, 1995Date of Patent: March 25, 1997Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5520913Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: July 6, 1993Date of Patent: May 28, 1996Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5411871Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: January 7, 1994Date of Patent: May 2, 1995Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5405771Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: January 7, 1994Date of Patent: April 11, 1995Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5366886Abstract: Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.Type: GrantFiled: February 11, 1993Date of Patent: November 22, 1994Assignee: Genentech, Inc.Inventors: Stephen P. Anderson, Deborah L. Higgins, Adair J. Hotchkiss, Cara B. Marks
-
Patent number: 5314818Abstract: Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.Type: GrantFiled: February 19, 1992Date of Patent: May 24, 1994Assignee: Genentech, Inc.Inventors: Stephen P. Anderson, Deborah L. Higgins, Adair J. Hotchkiss, Cara B. Marks
-
Patent number: 5262170Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: October 3, 1991Date of Patent: November 16, 1993Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5190756Abstract: A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.Type: GrantFiled: August 29, 1991Date of Patent: March 2, 1993Assignee: Genentech, Inc.Inventors: Francis J. Castellino, Deborah L. Higgins
-
Patent number: 5108901Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.Type: GrantFiled: July 24, 1989Date of Patent: April 28, 1992Assignee: Genentech, Inc.Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
-
Patent number: 5094953Abstract: Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.Type: GrantFiled: March 21, 1988Date of Patent: March 10, 1992Assignee: Genentech, Inc.Inventors: Stephen P. Anderson, Deborah L. Higgins, Adair J. Hotchkiss, Cara B. Marks
-
Patent number: 5087572Abstract: A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.Type: GrantFiled: December 1, 1989Date of Patent: February 11, 1992Assignee: Genentech, Inc.Inventors: Francis J. Castellino, Deborah L. Higgins
-
Patent number: 5037646Abstract: Disclosed herein are improved processes for preparing variant human t-PA proteins exhibiting improved pharmacokinetic properties relative to natural t-PA. One such illustrated variant, devoid of amino acids corresponding to amino acids 1 through 44 of natural t-PA, is shown to exhibit a plasma half-life of greater than about 15 times the plasma half-life to natural t-PA, as well as a clearance rate of less than about 1/10 the clearance rate of natural t-PA. Also disclosed are improved processes for treating vascular disease employing pharmaceutical compositions which incorporate therapeutically effective amounts of such t-PA variants with pharmaceutically acceptable diluents or excipients.Type: GrantFiled: June 18, 1990Date of Patent: August 6, 1991Assignee: Genentech, Inc.Inventors: Deborah L. Higgins, William E. Holmes, Adair J. Hotchkiss